Market closed
Outlook Therapeutics/$OTLK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Ticker
$OTLK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23
Website
OTLK Metrics
BasicAdvanced
$50M
-
-$4.06
0.54
-
Price and volume
Market cap
$50M
Beta
0.54
52-week high
$12.85
52-week low
$0.87
Average daily volume
1.1M
Financial strength
Current ratio
0.644
Quick ratio
0.351
Long term debt to equity
-0.338
Total debt to equity
-40.694
Interest coverage (TTM)
-22.71%
Management effectiveness
Return on assets (TTM)
-146.64%
Return on equity (TTM)
172.24%
Valuation
Price to book
-0.66
Price to tangible book (TTM)
-0.66
Price to free cash flow (TTM)
-0.545
Growth
Earnings per share change (TTM)
-13.83%
3-year earnings per share growth (CAGR)
-16.44%
What the Analysts think about OTLK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Outlook Therapeutics stock.
OTLK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
OTLK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
OTLK News
AllArticlesVideos
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
GlobeNewsWire·1 week ago
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
GlobeNewsWire·1 week ago
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Outlook Therapeutics stock?
Outlook Therapeutics (OTLK) has a market cap of $50M as of January 31, 2025.
What is the P/E ratio for Outlook Therapeutics stock?
The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of January 31, 2025.
Does Outlook Therapeutics stock pay dividends?
No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Outlook Therapeutics dividend payment date?
Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Outlook Therapeutics?
Outlook Therapeutics (OTLK) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.